Phase i and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

F. J. Giles; N. Vey; D. Rizzieri; F. Ravandi; T. Prebet; G. Borthakur; T. F. Jacobsen; S. Hagen; B. Nilsson; S. O'Brien

doi:10.1038/leu.2012.1

Phase i and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

F. J. Giles^*, N. Vey, D. Rizzieri, F. Ravandi, T. Prebet, G. Borthakur, T. F. Jacobsen, S. Hagen, B. Nilsson, S. O'Brien

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

20 Scopus citations

Original language	English (US)
Pages (from-to)	1686-1689
Number of pages	4
Journal	Leukemia
Volume	26
Issue number	7
DOIs	https://doi.org/10.1038/leu.2012.1
State	Published - Jul 2012

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2012.1

Cite this

@article{798282b57e6847ab825be18c356869df,

title = "Phase i and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies",

author = "Giles, {F. J.} and N. Vey and D. Rizzieri and F. Ravandi and T. Prebet and G. Borthakur and Jacobsen, {T. F.} and S. Hagen and B. Nilsson and S. O'Brien",

note = "Funding Information: This study was supported by the Canadian Institutes of Health Research (CIHR) and the Leukemia and Lymphoma Society of Canada (to DS) and a QEII-SST graduate scholarship from the University of Toronto (to ST). Funding Information: FJ Giles, N Vey, D Rizzieri and S O{\textquoteright}Brien have received research funding from Clavis Pharma. TF Jacobsen, S Hagen and B Nilsson are/were Clavis Pharma employees.",

year = "2012",

month = jul,

doi = "10.1038/leu.2012.1",

language = "English (US)",

volume = "26",

pages = "1686--1689",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Phase i and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

AU - Giles, F. J.

AU - Vey, N.

AU - Rizzieri, D.

AU - Ravandi, F.

AU - Prebet, T.

AU - Borthakur, G.

AU - Jacobsen, T. F.

AU - Hagen, S.

AU - Nilsson, B.

AU - O'Brien, S.

N1 - Funding Information: This study was supported by the Canadian Institutes of Health Research (CIHR) and the Leukemia and Lymphoma Society of Canada (to DS) and a QEII-SST graduate scholarship from the University of Toronto (to ST). Funding Information: FJ Giles, N Vey, D Rizzieri and S O’Brien have received research funding from Clavis Pharma. TF Jacobsen, S Hagen and B Nilsson are/were Clavis Pharma employees.

PY - 2012/7

Y1 - 2012/7

UR - http://www.scopus.com/inward/record.url?scp=84863779790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863779790&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.1

DO - 10.1038/leu.2012.1

M3 - Letter

C2 - 22222600

AN - SCOPUS:84863779790

SN - 0887-6924

VL - 26

SP - 1686

EP - 1689

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Phase i and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this